



NOTICE OF EXTRAORDINARY GENERAL MEETING IN ACARIX AB

The shareholders in Acarix AB (publ) corp. reg. no 559009-0667 (the "Company") are hereby convened to an extraordinary general meeting on Monday 27 October 2025 at 11.30 at Advokatfirman Lindahl's premises, Smålandsgatan 16 in Stockholm.

Notice etc.

Shareholders who wish to participate in the general meeting shall:

- be registered in the share register kept by Euroclear Sweden AB on Friday 17 October 2025 (the record date), and
- notify his or her intention to attend the general meeting to the Company no later than Friday 24 October 2025, by e-mail to christian.lindholm@acarix.com or by mail to Acarix AB, Att: Christian Lindholm, c/o Regus Hyllie, Hyllie Boulevard 34, 5 tr, 215 32 Malmö, stating "general meeting".

Such notification shall include the shareholder's name, Swedish personal identification number or corporate registration number, address and telephone number, number of shares, details on advisors (no more than two), if any, and, where applicable, details of representatives or proxies.

Nominee-registered shares

Shareholders whose shares are registered in the name of a nominee through a bank or other trustee must, in addition to notify his or her intention to attend the general meeting, register their shares in their own name so that the shareholder is included in the share register kept by Euroclear Sweden on 17 October 2025. Such registration may be temporary (so-called voting rights registration) and shall be requested by shareholders in such time and in accordance with the routines that the nominee determines. Voting rights registrations that have been completed by the nominee no later than 21 October 2025 will be considered in the preparation of the share register.

Proxy

Shareholders represented by proxy must submit a dated power of attorney. If the power of attorney is executed by a legal person, a copy of the certificate of registration or equivalent must be attached. The power of attorney may not be valid for a period exceeding five years from its issuance. The original power of attorney and certificate of registration should be submitted to the Company by mail at the address mentioned above in due time prior to the general meeting. Alternatively, the original power of attorney and certificate of registration may be brought and presented at the general meeting. The Company provides a power of attorney form at request and on the Company's website, www.acarix.com.



Number of shares and votes

As of the date of this notice, there are a total of 1,123,320,142 shares and votes in the Company.

Proposed agenda

1. Opening of the general meeting and election of chairman of the general meeting
2. Preparation and approval of the voting list
3. Election of one or two persons to verify the minutes
4. Approval of the agenda
5. Determination as to whether the meeting has been duly convened
6. Resolution to change the terms in the Employee Stock Option Program 2025/2029
7. Closing of the general meeting

Proposals for resolutions

Item 1 – Election of chairman of the general meeting

The nomination committee proposes that Mattias Prage, lawyer at Advokatfirman Lindahl, is elected as chairman of the general meeting or, in his absence, the person otherwise appointed by the board of directors.

Item 6 – Resolution to change the terms in the Employee Stock Option Program 2025/2029

The general meeting of the Company resolved on 13 May 2025 on an employee stock option program intended for the Company's executive management (the "**Employee Stock Option Program 2025/2029**" or the "**Program**"). The resolution also included an issue of warrants to the Company to ensure the implementation of the Program. The Program comprised a total of 20,000,000 employee stock options.

The board of directors proposes that the general meeting resolves to adjust the conditions for participation in the Program as set out below. The board's assessment is that the Program through these amendments would be more appropriate, including the possibility to allocate the employee stock options to consultants engaged in the business and to all employees of the Company (not only to executive management). It is worth emphasising that no changes are made to the volume (i.e. number of stock options) or the exercise price.

The board of directors proposes that the general meeting resolves on the following:

1. Employee stock options from the Employee Stock Option Program 2025/2029 can be granted to both consultants and employees of the Company (or its group companies).
2. Previous specific conditions and criteria for the CEO compared to other employees are removed – all employees shall be treated according to equal conditions.
3. Participation in the Employee Stock Option Program 2025/2029 is not subject to geographical restrictions and can thus be offered to participants outside Sweden as well.



4. Employee stock options allocated to consultants shall as a general rule vest with fifty (50) per cent twelve (12) months after allocation and with an additional fifty (50) per cent twenty-four (24) months after allocation.
5. Allocated employee stock options vest over three years as follows:
 - one third (1/3) vest immediately upon allocation;
 - two-thirds (2/3) vest two years after allocation; and
 - all employee stock options are vested three years after allocation.
6. If the board deems it appropriate for commercial reasons, the board may decide to deviate from the schedule above (both section 4 and 5) for one or more participants, provided that such deviations are documented and do not materially change the fundamental structure of the Program.
7. Participation in the Program, vesting, allocation or exercise of employee stock options is not conditional upon any strategic or operational objectives (but the board has the possibility to introduce such objectives for one or more participants). The board has evaluated the possibility of including the above-mentioned targets, but after consideration has concluded that the Program will be more effective without any strict requirement for such targets (which can be challenging to both set and monitor in a volatile market).

In addition to the above proposed adjustments, the conditions previously resolved by the general meeting under items A, B and C shall continue to apply. The terms and conditions for the Employee Stock Option Program 2025/2029 will be reworded after the proposed amendments and are set out in full in a separate appendix.

Dilution

No change in dilution will arise as a result of the board's proposed amendments.

Costs

The proposed amendments do not entail any changes to the Company's costs attributable to Employee Stock Option Program 2025/2029.

Majority requirements

Resolutions according to item 6 above require, for its validity, a minimum of nine tenths of both the votes cast and the shares represented at the general meeting.

Processing of personal data

For information regarding the processing of your personal data, please refer to <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>

The shareholders' right to information at the general meeting



The board of directors and the CEO shall, up request by any shareholder, and where the board of directors deems that such information may be provided without significant harm to the Company, provide information in respect of any circumstances which may affect the assessment of a matter on the agenda or the Company's financial position as well as the Company's relationship to other group companies. Shareholders can submit questions in advance to the Company, to the address Acarix AB, c/o Regus Hyllie, Hyllie Boulevard 34, 5 tr, 215 32 Malmö or by e-mail to christian.lindholm@acarix.com.

Documents

Documents according to the Swedish Companies Act will be held available at the Company at c/o Regus Hyllie, Hyllie Boulevard 34, 5 tr, 215 32 Malmö and at the Company's website, www.acarix.com, no later than two weeks before the meeting, *i.e.*, no later than 13 October 2025. The documents will also be sent, without charge, to shareholders who so request and inform the Company of their postal address.

Malmö in October 2025

Acarix AB

The board of directors

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 40,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

For more information, contact

Macie May, phone +1 405 517 5161, email mmay@saxum.com

Attachments

[NOTICE OF EXTRAORDINARY GENERAL MEETING IN ACARIX AB](#)